# Verrica Pharmaceuticals Inc.

**VRCA**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001660334

# None

**No letter**

6 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $47.1M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, thin data; fortress balance sh...<br>not computable: distress |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Mar 11, 2026<br>244 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $3.25<br>2026-11-06; market equity $55.8M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 11, 2026*

We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Our commercial product, YCANTH (VP-102), was approved by the U.S.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 80.1** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (0.5%) | (6.6%) | 80.1 | 800 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 2* | | | | | | |
| **Solvency, sleeve percentile 67.2** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | (19.42) | (0.35) | 73.1 | 745 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 2.59x | 2.95x | 61.3 | 826 | 2025-12-31 | |
| **Growth and financing, sleeve percentile 46.9** | | | | | | |
| Revenue growth, three-year compound | 57.9% | 10.1% | 11.5 | 411 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | 1.8% | 2.2% | 48.2 | 694 | 2025-12-31 | |
| Net share issuance, one year | 87.2% | 2.5% | 80.9 | 629 | 2026-03-02 | |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 87.2% |
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |
| Fortress balance sheet | cash minus debt is 30,147,000 USD; Altman Z is not used |

## What the price implies

*at the 2026-11-06 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 32.8% | (1.9%) | 71 |
| Distance from 52-week high | (60.5%) | (27.5%) | 19 |
| EBIT to enterprise value | (24.1%) | (1.5%) | 23 |
| Free cash flow yield | (28.6%) | (1.0%) | 20 |
| Book value to price | 0.07 | 0.27 | 21 |
| Sales to price | 0.58 | 0.29 | 70 |
| Composite equity issuance, five years | 191.0% | 20.8% | 88 |
| Relative strength against the sector, log excess return | 0.12 | (0.19) | 71 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | pass |
| Current ratio improved | pass |
| No new shares issued | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $11.2M |
| Operating cash flow, four quarters | -$13.3M |
| Months of runway | 10.1 |
| Days since last periodic filing | 96 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $218,804 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $7.6M | 2024-12-31 | 2025-03-11 | 10-K | 25-037172 |
| 2 | cost of revenue | us-gaap:CostOfRevenue | $2.6M | 2024-12-31 | 2025-03-11 | 10-K | 25-037172 |
| 3 | assets | us-gaap:Assets | $54.1M | 2024-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 4 | net income | us-gaap:NetIncomeLoss | -$17.9M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$17.6M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 6 | assets | us-gaap:Assets | $47.1M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 7 | current assets | us-gaap:AssetsCurrent | $42.5M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $16.4M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$324.9M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 10 | operating income | us-gaap:OperatingIncomeLoss | -$12.2M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 11 | book equity | us-gaap:StockholdersEquity | $24.7M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 12 | liabilities | us-gaap:Liabilities | $22.4M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 13 | total debt | us-gaap:LongTermDebt | $0 | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 14 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $30.1M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 15 | depreciation amortization | us-gaap:Depreciation | $133,000 | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 16 | operating income | us-gaap:OperatingIncomeLoss | -$65.8M | 2023-12-31 | 2025-03-11 | 10-K | 25-037172 |
| 17 | interest expense | us-gaap:InterestExpense | $4.0M | 2023-12-31 | 2024-02-29 | 10-K | 24-022659 |
| 18 | revenue | us-gaap:Revenues | $35.6M | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $5.1M | 2023-12-31 | 2025-03-11 | 10-K | 25-037172 |
| 20 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $9.0M | 2022-12-31 | 2024-02-29 | 10-K | 24-022659 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $0 | 2025-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$60.9M | 2024-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $27,000 | 2024-12-31 | 2026-03-11 | 10-K | 26-000008 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$38.6M | 2023-12-31 | 2025-03-11 | 10-K | 25-037172 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $362,000 | 2023-12-31 | 2025-03-11 | 10-K | 25-037172 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$18.6M | 2022-12-31 | 2024-02-29 | 10-K | 24-022659 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $302,000 | 2022-12-31 | 2024-02-29 | 10-K | 24-022659 |
| 28 | assets | us-gaap:Assets | $81.6M | 2023-12-31 | 2025-03-11 | 10-K | 25-037172 |
| 29 | assets | us-gaap:Assets | $44.7M | 2022-12-31 | 2024-02-29 | 10-K | 24-022659 |
| 30 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 17,178,786 | 2026-03-02 | 2026-03-11 | 10-K | 26-000008 |
| 31 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 91,779,993 | 2025-03-05 | 2025-03-11 | 10-K | 25-037172 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.